OSTX SEC Filings: 8-K, 10-Q, S-3 & 424B – OS Therapies

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 18, 2026

NT 10-Q

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

May 15, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 18, 2025

News

TYPE

HEADLINE

FILED AT

8-K

OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Approximately $7.2 Million in Gross Proceeds

Oct 19, 2026

8-K

OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer

Oct 5, 2026

8-K

OS Therapies Incorporated Files Prospectus Supplement for Resale of up to 5,874,094 Shares of Common Stock

Sep 10, 2026

8-K

OS Therapies Incorporated Reports Voting Results from 2026 Annual Meeting

Sep 9, 2026

8-K

OS Therapies Incorporated Enters into $75 Million "At the Market" Equity Offering Program

Aug 21, 2026

8-K

OS Therapies Incorporated Announces $10 Million Private Placement Financing

Aug 12, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B7

SHARE RESALE REGISTRATION | Shares: 5,874,094

Sep 10, 2026

424B5

August 2026 ATM | Offering amount: $75,000,000 | Bank: Jefferies LLC

Aug 21, 2026

424B5

OFFERING - OTHER | Shares: 500,000

Aug 6, 2026

424B5

REGISTERED OFFERING

Apr 2, 2026

424B7

SHARE RESALE REGISTRATION | Shares: 10,529,417

Mar 31, 2026

424B7

SHARE RESALE REGISTRATION | Shares amount: 4,373,043 | Warrants amount: 3,373,043 |

Sep 30, 2025

Registrations

TYPE

HEADLINE

FILED AT